Open AccessPsoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study
Author(s) -
Anna Campanati,
Federico Diotallevi,
Giulia Radi,
Elisa Molinelli,
Valerio Brisigotti,
Emanuela Martina,
Matteo Paolinelli,
Tommaso Bianchelli,
C. Cosimo S. Covi,
Marta Bartezaghi,
Annamaria Offidani
Publication year - 2021
Publication title -
european journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.48
H-Index - 71
eISSN - 1952-4013
pISSN - 1167-1122
DOI - 10.1684/ejd.2021.4150
Subject(s) - secukinumab , medicine , dermatology , disease , psoriasis , psoriatic arthritis
Achieving minimal disease activity (MDA) represents an ambitious and sustainable therapeutic goal in psoriasis. Clear criteria for defining MDA in psoriasis are lacking.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom